Natco Pharma Ltd (NATCOPHARM)
₹782.40
Mkt cap
₹15,348 Cr
P/E ratio
13.40
P/B
1.66
Div yield
0.64%
ROE
17.10%
ROCE
17.40%
EPS (TTM)
₹58.39
Book value
₹470
52W range
774–1,217
Sector
Healthcare
Price history
Previous close
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1] NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business. [2]
NSE NATCOPHARMBSE 524816
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−35.70% from high₹782
₹774+1.14% from low₹1,217
Current
₹782.40
Prev close
₹787.55
Day
−0.65%
Price performance
1D
−0.69%
1W
−1.22%
1M
−6.47%
3M
−15.19%
6M
−27.89%
1Y
−5.47%
YTD
−11.67%
Financials
Revenue, profit & margin
P/E ratio
13.4×
NATCOPHARM is 61% below the sector median of 34.0×
NATCOPHARM13.4×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,140 | 1,031 | 759 | 1,068 | 1,363 | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 | |
| Expenses | 612 | 573 | 490 | 571 | 558 | 567 | 436 | 673 | 758 | 784 | 489 | 612 | 549 | |
| Operating Profit | 528 | 458 | 268 | 497 | 805 | 804 | 39 | 548 | 571 | 579 | 159 | 128 | 186 | |
| OPM % | 46% | 44% | 35% | 47% | 59% | 59% | 8% | 45% | 43% | 42% | 25% | 17% | 25% | |
| Other Income | 20 | 29 | 37 | 42 | 48 | 64 | 176 | 66 | 62 | 100 | 58 | 78 | 59 | |
| Interest | 4 | 4 | 5 | 6 | 5 | 4 | 4 | 10 | 3 | 13 | 10 | 11 | 13 | |
| Depreciation | 44 | 44 | 44 | 56 | 44 | 46 | 47 | 98 | 58 | 52 | 46 | 50 | 47 | |
| Profit before tax | 500 | 440 | 256 | 478 | 804 | 818 | 164 | 506 | 572 | 614 | 161 | 144 | 186 | |
| Tax % | 16% | 16% | 17% | 19% | 17% | 17% | 19% | 20% | 16% | 16% | 13% | -62% | 34% | |
| Net Profit | 420 | 369 | 213 | 386 | 668 | 676 | 132 | 406 | 480 | 518 | 151 | 269 | 206 | |
| EPS in Rs | 21.42 | 18.81 | 10.84 | 19.69 | 34.07 | 34.52 | 6.78 | 20.72 | 24.50 | 26.42 | 7.72 | 13.65 | 10.52 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
13 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.14% · closed higher next day 29 of last 60
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 14 Nov '23◦ | 14 Feb '24◦ | 27 May '24◦ | 12 Aug '24◦ | 12 Nov '24◦ | 12 Feb '25◦ | 28 May '25◦ | 12 Aug '25 | 14 Nov '25◦ | 12 Feb '26 | 29 May '26 | 14 Aug '26 |
| Earnings day | −4.48% | +0.26% | +0.28% | −1.30% | −1.72% | −20.00% | +3.64% | −1.28% | +1.02% | −1.29% | −13.60% | −5.10% |
| +1 day | −2.63% | +16.01% | +1.15% | −2.38% | −1.03% | −27.54% | +2.45% | +0.49% | +0.23% | −3.17% | −20.62% | −6.50% |
| +5 days | +0.67% | +14.03% | −5.74% | −1.51% | −2.39% | −34.92% | −0.06% | −1.22% | +3.52% | +4.41% | −24.02% | −7.28% |
| +15 days | −1.48% | +14.76% | +13.90% | +4.15% | +4.25% | −32.31% | +2.24% | −4.92% | +10.47% | +19.85% | −24.39% | −12.93% |
| +30 days | +2.15% | +12.94% | +15.02% | −5.23% | +0.47% | −33.96% | +15.77% | −6.39% | +10.41% | +14.50% | −16.66% | −12.94% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| rights Rights 2:21 @ Premium Rs 748/- | — | 1 Oct '26 | 1 Oct '26 |
Shareholding
as of Sep 202649.39%Promoter
Promoters49.39%0.02
FIIs15.99%1.00
DIIs6.16%0.53
Public28.46%0.49
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Natco Pharma | ₹782.40 | 13.41 | 15,348 | 0.64% | 207 | −57.04% | 735 | −44.68% | 17.39% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts99
TranscriptAug 2026PPTAug 2026RECAug 2026PPTAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptJul 2025PPTJul 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025
Credit ratings6
Announcements5
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 30 Oct - Promoters acquired rights issue shares on 26 Oct 2026; Venkaiah Chowdary bought 5.86 lakh shares.Board Meeting Intimation for Considering Un-Audited Financial Results For The Quarter Ended 30Th September, 2026 And Declaration Of Second Interim Dividend, If Any 29 Oct - Board meeting on 13 November 2026 to consider Q2/H1 FY2026-27 results and second interim dividend.Announcement under Regulation 30 (LODR)-Newspaper Publication 29 Oct - News Paper Publication for Basis of Allotment of Right IssueAnnouncement under Regulation 30 (LODR)-Allotment 23 Oct - Natco Pharma allotted 1.70 crore rights shares at ₹750 each on October 23, 2026.Closure of Trading Window 22 Oct